Distribution NIlotinib in semen in men treated for chronic Myeloid leukAemia
Recruiting
- Conditions
- CM
- Registration Number
- NL-OMON26150
- Lead Sponsor
- VU University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
•male patients
•aged >18 years
Exclusion Criteria
•Refractory CML with persistent leucocytosis
•Sterilisation
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of nilotinib present in seminal fluid in relation to the plasma concentration.
- Secondary Outcome Measures
Name Time Method Calculated maximal concentration nilotinib absorbed by the partner, using the volume of distribution of the tyrosine kinase inhibitors and the percentage in seminal fluid found in this study.